Keystone Symposia

This meeting took place in 2015

For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Pathways of Neurodevelopmental Disorders (C8)

Organizer(s) Randi J. Hagerman, Mustafa Sahin and Paul J. Hagerman
March 16—20, 2015
Granlibakken Tahoe • Tahoe City, CA USA
Discounted Abstract Deadline: Nov 18, 2014
Abstract Deadline: Dec 16, 2014
Scholarship Deadline: Nov 18, 2014
Discounted Registration Deadline: Jan 15, 2015

Sponsored by BioLegend, Inc., California Institute for Regenerative Medicine (CIRM), Curemark LLC and FORUM Pharmaceuticals Inc.

Summary of Meeting:
Advances in genetics and animal models for many neurodevelopmental disorders have led to the development of targeted treatments that can reverse neurobiological abnormalities in the animal models. Human studies have begun to show significant benefit from targeted treatments for several neurodevelopmental disorders including fragile X syndrome, tuberous sclerosis, Angelman Syndrome, Down Syndrome, Rett Syndrome and neurofibromatosis, with the potential for many more. There are remarkable commonalities in the dysfunction of key pathways and the molecular mechanisms involved in synaptic plasticity across neurodevelopmental disorders. This Keystone Symposia meeting covers advances in targeted treatments for several neurodevelopmental disorders with an emphasis on common pathways across disorders and treatments that may help more than one disorder. The conference also addresses the gap between how environmental factors including seizures and toxins can impact genetically vulnerable populations, such as those with neurodevelopmental problems, and the molecular mechanisms including mitochondrial dysfunction, oxidative stress, miRNA dysregulation and neuroinflammation that are involved. The goal of this conference is to stimulate development of new treatments and biomarkers to assess treatments in neurodevelopmental disorders and to promote early intervention with prophylactic and targeted treatments. By pulling together basic science and translational clinical trials, and mixing clinicians with molecular biologists and neurobiologists, the meeting should foster new ideas for treatment that will be beneficial across the spectrum of neurodevelopmental disorders.

View Meeting Program


National Institute of General Medical Sciences (NIGMS) Ancillary Training Program Scholarship Recipients

Rosa Martinez-Garcia
Brown University, USA

National Institute of Neurological Disorders and Stroke (NINDS) Scholarship Recipients

Ashley G. Anderson
University of Texas Southwestern Medical Center, USA

Jason Arsenault
University of Toronto, Canada

Jui-Yen Huang
Baylor College of Medicine, USA

Gaelle Robin
Sanford Burnham Prebys Medical Discovery Institute, USA

Ki-Jun Yoon
Korea Advanced Institute of Science and Technology, South Korea